Commentary Open Access
A Commentary on “Suppressive Effect of Topical Moxifloxacin on Imiquimod-Induced Model of Psoriasis in Mice”
Alaa Hamza Abbas1,*
- 1Al-Mustaqbal University, College of Pharmacy, 51001 Hillah, Babylon, Iraq
Corresponding Author
Alaa Hamza Abbas, alla1979200713@yahoo.com
Received Date: July 03, 2025
Accepted Date: September 22, 2025
Abbas AH. A Commentary on “Suppressive Effect of Topical Moxifloxacin on Imiquimod-Induced Model of Psoriasis in Mice”. J Exp Neurol. 2025;6(4):162–165.
Copyright: © Abbas AH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Maternal Psoriasis – Pregnancy Outcomes and Long-term Infectious Morbidity of the Offspring: A Population-based Study
Background: Limited data exists regarding long-term morbidity of the offspring in women with psoriasis. The objective of this study was to assess long-term infectious morbidity of the offspring born to women with psoriasis. Study Design: We conducted a population-based cohort study comparing the long-term infectious-related morbidity of offspring (up to the age of 18) born to mothers with and without psoriasis, between the years 1991-2021 in a regional tertiary medical center.
A Commentary on “Suppressive Effect of Topical Moxifloxacin on Imiquimod-Induced Model of Psoriasis in Mice”
The Journal of Experimental Neurology frequently highlights studies that bridge the gap between neurological disorders and systemic conditions, particularly those with an immunological component. The recent article, "Suppressive Effect of Topical Moxifloxacin on Imiquimod-Induced Model of Psoriasis in Mice," by Abbas et al., presents intriguing data suggesting a potential role for the fluoroquinolone antibiotic moxifloxacin in the treatment of psoriasis, a chronic inflammatory skin disorder.